BioXcel Therapeutics Securities Settlement
$1.10–$1.52
This settlement is closed to new claims — the deadline was June 30, 2026. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
BioXcel Therapeutics and its executives allegedly violated federal securities laws by making materially false or misleading statements and omissions regarding the company's business. Defendants deny wrongdoing and settled to avoid the costs and risks of continued litigation.
Do you qualify?
Anyone who purchased or acquired BioXcel Therapeutics, Inc. common stock (CUSIP: 09075P204) between March 9, 2023 and June 28, 2023, inclusive.
How to file
Submit a valid Proof of Claim and Release Form online or by mail postmarked on or before June 30, 2026. The form requires documentation of your securities purchases. You can file online at the settlement website or mail to Strategic Claims Services, 600 N. Jackson St., Suite 205, Media, PA 19063.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Tattooed Chef Securities Settlement
Tattooed Chef, Inc. faced a securities lawsuit alleging that purchasers of the company's common stock were damaged. The defendant has agreed to settle all claims in the action for $4,750,000 in cash without admitting wrongdoing.
Estée Lauder Securities Settlement
Estée Lauder is settling securities litigation relating to alleged damages to investors who purchased or acquired publicly traded common stock of The Estée Lauder Companies Inc. during the class period. The defendant has not admitted wrongdoing in this settlement.
E-Commerce China Dangdang Securities Settlement
E-Commerce China Dangdang, Inc. was involved in a take-private transaction (merger) that closed on September 20, 2016. Shareholders who held American Depositary Shares during the Class Period claim they were harmed by undisclosed information related to the Company's take-private transaction. The defendant has agreed to settle these securities claims without admitting wrongdoing.
Evolv Technologies Holdings Securities Settlement
Investors purchased publicly traded common stock of Evolv Technologies Holdings Inc. during a specific period and are entitled to compensation from a securities class action settlement. The page does not explicitly state what wrongdoing Evolv allegedly committed.